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CLINICAL SCIENCE
Evaluation of a Systematic Substitution of Zidovudine
for Stavudine-Based HAART in a Program Setting
in Rural Cambodia
Petros Isaakidis, MD, PhD,* Marie-Eve Raguenaud, MD, MSc,* Thong Phe, MD, MSc,*
Sam A. Khim, MD,* Sokhan Kuoch, MD,† Sopheap Khem,* Tony Reid, MD,‡ and Line Arnould, MD‡
Objective: To evaluate a treatment strategy of substituting
zidovudine (ZDV) for stavudine (d4T)-based highly active anti-
retroviral therapy (HAART), aimed at preventing d4T-associated
toxicity, in a programmatic setting in rural Cambodia.
Methods: Survival probability, CD4 gain, anemia incidence, and
factors associated with severe anemia were analyzed in a cohort of
adult patients switched from d4T- to ZDV-containing regimens from
March 2006 to March 2007.
Results: Among 527 patients systematically switched to ZDVafter
d4T-based HAART for a median of 18 months, 4 (0.8%) patients
died, 2 (0.4%) were lost to follow-up, 18 (3.4%) were transferred out,
a n d5 0 3( 9 5 . 4 % )r e m a i n e do nH A A R T .M e d i a nC D 4g a i nw a s1263.5
cells/mL (interquartile range: 89.25–369.5) at 24 months. Within 1 year
after the switch, 21.9% and 7.1% of patients developed anemia (grades
1–4) and severe anemia (grades 3–4), respectively. Low body mass
index (#18) and low CD4 count (,200 cells/mL) at the time of switch
were factors associated with severe anemia. Additional follow-up visits
for laboratory monitoring and adherence counseling, increased absen-
teeism from work, and transportation costs for the patients were noted.
Conclusions: The switch strategy of substituting ZDV for d4T-
based HAART led to satisfactory overall clinical outcomes. However,
it resulted in a relatively high incidence of mild to severe anemia and
increased burden for the program and the patients.
Key Words: zidovudine, stavudine, substitution, highly active
antiretroviral treatment (HAART), resource-limited settings
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INTRODUCTION
The feasibility and efﬁcacy of standardized highly active
antiretroviral therapy (HAART) in resource-limited settings
are increasingly being documented.
1–7 However, the limited
number of available and affordable antiretroviral drugs in these
settings is hampering the necessarytreatment changes required
in cases of toxicity, contraindications, or treatment failure.
Stavudine (d4T) has been one of the most frequently
prescribed nucleoside reverse transcriptase inhibitors (NRTIs)
in initial ﬁrst-line regimens in Cambodia, as in most resource-
poor settings. Its availability at low-cost, ﬁxed-dose combi-
nations, its efﬁcacy, and relatively low short-term toxicity that
enhances patient adherence and limits the need for laboratory
monitoring made it an attractive drug for standardized
regimens.
8 However, there is increasing evidence that d4T is
one of the NRTIs most associated with long-term mitochon-
drial toxicity, and it is therefore no longer recommended by
World Health Organization (WHO) as the preferred NRTI.
9–11
Very limited evidence regarding treatment strategies to
prevent the d4T-associated toxicity in resource-restricted settings
is available.
12,13 Meanwhile, zidovudine (ZDV) is becoming
increasingly affordable and available despite concerns about its
short-term tolerability, especially the risk of anemia among
patients with advanced disease, women, and individuals with
low body mass index (BMI).
14,15 Apromisingstrategytoprevent
d4T toxicity has been suggested based on experts’ advice:
a switch from d4T to ZDVafter several months of HAART.
12,13
The rationale for this change is to prevent the long-term
toxicities associated with d4T, although retaining its beneﬁts in
the short term, taking into account the potential risk of anemia of
initial ZDV-based regimens. Evidence for this switch strategy is
very limited, but one study, with a small cohort of patients and
a switch after 6 months, found the incidence of anemia to be less
than expected.
12 Our study hada larger cohort of patients and the
switch occurred later so that it provides additional evidence
regarding the advisability of the switch strategy.
Since March 2006, the treatment protocol for HIV/AIDS
patients in Takeo Hospital, a referral hospital in rural Cambodia
run by Ministry of Health and supported by Medecins Sans
Frontie `res, implemented a systematic switch from a d4T- to
a ZDV-based regimen, after at least 6 months of HAART. The
purpose of this study is to describe the results of the switch
strategy, including survival indicators, the incidence of side
effects, notably anemia and its risk factors, and adherence and
implications for clinical programing and for the patients.
METHODS
Study Design
This was a retrospective, observational study using data
routinely collected at each consultation and entered prospectively
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Infection and AIDS, Epicentre, Paris).
The study was approved by the Ethical Review Board
of Me ´decins Sans Frontie `res on October 1, 2007 and by the
National Ethics Committee for Health Research of Cambodia
on October 8, 2007.
Setting
Me ´decins Sans Frontie `res, in collaboration with the
National Center for HIV/AIDS, Dermatology, and STDs and
theMinistryofHealth,has beensupportingtheChronicDisease
Clinic of the Donkeo Referral Hospital in Takeo Province,
South Cambodia, since 2003. An HAART was offered free of
charge to patients either at WHO stages I, II, or III with CD4
count #200 cells/mL or at WHO stage IV (AIDS) irrespective
of CD4 count as per WHO recommendations and the national
HAART protocol. Most patients were initiated on a ﬁxed-dose
combination of stavudine–lamivudine–nevirapine whereas in
case of contraindications or intolerance, alternative regimens
were offered [including ZDV , tenofovir (TDF), efavirenz, and
protease inhibitors]. ZDV- or TDF-based HAART regimens
were not prescribed as initial regimens because of concerns
about the tolerability of ZDV , especially the risk of anemia, and
because of the limited availability of TDF in Cambodia.
Study Population
The study population included all adults, aged 15 years
or more, whowere systematically switched from d4T- to ZDV-
based HAART after at least 6 months of treatment. Nonnaive
patients, those with less than 3 months of follow-up after the
switch and thosewith hemoglobin (Hb) less than 8.0 g/dL, and
patients with blood test results not recorded in their medical
ﬁles were excluded from the analysis.
Switch Strategy
From March 2006, all new patients initiated on d4T-
based HAART were eligible for a systematic switch to ZDV
after 6 months and all patients in the cohort already on a d4T-
based HAART regimen for at least 6 months were switched to
ZDV-based HAART. If in subsequent measurements Hb
decreased by 30% from the previous level or from baseline or
peak level, ZDV was ceased and a TDF-based regimen was
offered. Patients with other side effects were also changed
from ZDV . From the time of the drug switch, each patient was
required to come on a biweekly basis during the ﬁrst month,
then on a monthly basis till 6 months, and then every 2–3
months thereafter for monitoring and drug education.
Outcome Measurements
Outcomes including death, loss to follow-up, and
transfer out were recorded at the end of the observation
period, June 30, 2007. CD4 counts were performed at baseline
and every 6 months thereafter, using ﬂow cytometry
(Facscount; Beckton Dickinson, San Jose, CA) at the Donkeo
Referral Hospital, in Takeo. Hb measurements were taken at
the time of switch, at weeks 2, 4, 8, and 12, at month 6, and
every 6months thereafter.Anemiawas gradedaccording to the
AIDS Clinical Trials Group criteria
16; grade 1: Hb 8.0 to ,9.5
g/dL, grade 2: 7.0 to ,8.0 g/dL,grade 3: 6.5 to ,7.0 g/dL, and
grade 4: ,6.5 g/dL. The incidence rate of anemia was deﬁned
as the number of patients with at least one follow-up Hb ,9.5
g/dL (threshold forgrade 1 anemia) per 100 person-years of at-
risk follow-up. The follow-up period, during which the patient
was considered at risk, started on the day of the treatment
change (d4T to ZDV) and continued to the date of the last
follow-up or date of death or loss to follow-up or the date of
the ﬁrst blood cell count showing a value below the corre-
sponding threshold.
Statistical Analysis
Overall survival probability and anemia-free survival
probability were estimated using the Kaplan–Meier method.
Incidence rates of ZDV-associated hematological adverse events
were recorded. Anemia greater than grade 2 (serum Hb value
under 7.0 g/dL) within 12 months after ZDV initiation was
designated as the dependent variable for identifying potential risk
associations. The measures of risk were determined by crude
odds ratios and adjusted odds ratios. Odds ratios were adjusted
using multivariable logistic regression, and all related P values
were based on the Walds test. The x
2 test for linear trends was
alsoused.The level of signiﬁcancewasset at P=0.05orless,and
95% conﬁdence intervals (CIs) were used throughout. The
analysis considered data until June 30, 2007. Analyses were
performed using STATA 7.0 (STATACorp, College Station, TX).
RESULTS
Patients and Follow-up
From August 2003 to March 2007, 1693 patients above
15 years of age had started HAART, 1638 of them on a d4T-
based regimen. Nine hundred twenty patients had stopped d4T
and were taking a ZDV-based regimen for any reason by June
2007. Of 689 patients, who were switched to ZDV
systematically and not because of toxicity or other reasons,
527 were included in the analyses. Patients excluded from the
analyses included 104 patients with less than 3-month follow-
up after the treatment change, 45 patients with less than 2 Hb
values after the treatment change, and 13 patients nonnaive for
HAART (Fig. 1). The main baseline and follow-up character-
istics of the remaining 527 patients are shown in Table 1.
Seventeen patients (3.0%) had anemia at the time of switch,
including 7 with greater than or equal to grade 2 anemia. The
enrollment of these 7 patients represented a treatment protocol
deviation, and they were excluded from the analysis of anemia
over time. The median time on d4T before switching to ZDV
was approximately 18 months. The median follow-up after
ZDV initiation was approximately 10 months.
Clinical and Immunological Outcomes and
Patient Survival
Among the 527 patients included in the analysis, 4 (0.8%)
patients died, 2 (0.4%) were lost to follow-up, 18 (3.4%) were
transferred to another health facility, and 503 (95.4%) remained
on HAARTat the end of the observation period (Table 1). Causes
of death included severe anemia for 1 patient, severe oppor-
tunistic infection for 2 patients, and unknown for 1 patient.
Estimates of survival by the Kaplan–Meier method were
0.9981 at 12 months (95% CI 0.9865 to 0.9997) and 0.9937
at 24 months (95% CI 0.9807 to 0.9980) when death and loss
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at the time of HAART initiation was 61 cells/mL [interquartile
range (IQR): 16–148.5]. Among patients with available CD4
count at the time of switch (n = 527), median CD4 gain was
found to be +121.5 cells/mL (IQR: 81.25–177.75) at 6 months
(n = 518), +180 (IQR: 124–249) at 12 months (n = 507),
and 1263.5 (IQR: 189.25–369.5) at 24 months (n = 386).
One hundred ﬁfty-six (29.8%) patients experienced
a drop in CD4 count between the time of switch and the end of
the observation period. However, only 5 patients had a drop in
CD4 that met WHO criteria for immunological failure.
9 Two
patients had a detectableviral load (VL), 2 had an undetectable
VL, and 1 was still on follow-up at the time of the analysis.
Incidence and Characteristics of Anemia
Over Time
Overall, 114 (21.9%) patients developed an episode of
anemia of greater than or equal to grade 1 within 1 year after
starting ZDV (Table 2) whereas 7.1% of them developed
severe anemia (grades 3–4). The overall incidence rate of
grades 1–4 anemia was 31.83/100 person-years (95% CI 26.7
to 37.9), and the incidence rate of severe anemia was 10.0%
(95% CI 7.3 to 13.7) (Table 3).
Figure 2 shows the Kaplan–Meier estimate of the
probabilityofbeinganemiafreeat1year after starting the ZDV-
based regimen to be about 0.75.
Factors Associated With Incident Anemia
In univariate analysis, age, sex, and duration on d4T-
based regimen before switch were not associated with the risk
FIGURE 1. Patient ﬂow chart.
TABLE 1. Baseline and Follow-up Characteristics of
HIV-Positive Patients Who Were Systematically Switched
From D4T- to ZDV-Based Regimen (n = 527)
Male/female, n (%) 227/300 (43/57)
Age, yrs, median (IQR) 35 (30–40)
On CMX at time of switch, n (%) 172 (33)
WHO clinical stage at time of switch, n (%)
I 7 (1)
II 50 (9)
III 150 (29)
IV 320 (61)
CD4 count, mm
3, at time of switch
0–99 18 (3)
100–199 110 (21)
200–499 327 (62)
$500 72 (14)
CD4 count, mm
3, at time of switch,
median (IQR) 308 (202–419)
Body mass index, kg/m
2, n (%)
,16.0 severe malnutrition 6 (1)
16.0–16.9 moderate malnutrition 6 (1)
17.0–18.0 mild malnutrition 86 (16)
.18.0 normal nutrition 429 (81)
HAART regimen, n (%)
3TC + d4T + EFV 43 (8)
3TC + d4T + NVP 484 (92)
Hb level, g/L, median (IQR) 12.8 (11.6–14.0)
Anemia grade
.9.5 (normal) 510 (97)
8.0 to ,9.5 (grade 1) 10 (2)
7.0 to ,8.0 (grade 2) 6 (1)*
6.5 to ,7.0 (grade 3) 1 (0)*
,6.5 (grade 4) 0
No. days on d4T before ZDV switch,
median (IQR) (range) 546 (428–725) (91–116)
No. days on ZDV before stopped, n = 54,
median (IQR) (range)
109.5 (74.75–231.5) (6–1030)
Follow-up until ZDV stop or until last
consultation or death
Cumulative, person-days 168,604
Per patient, d, median (IQR) (range) 309 (187–428) (6–1087)
Outcomes at study termination, n (%)
Dead 4 (0.8)
Alive 503 (95.4)
Lost to follow-up 2 (0.4)
Transferred out 18 (3.4)
CMX, co-trimoxazole; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine
*Protocol deviation: eligibility criteria included Hb 8.0 g/dL.
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within 1 year after the switch were higher in patients with CD4
count less than 200/mm
3 at the time of ZDV initiation, in
malnourished patients, and in patients on co-trimoxazole
prophylaxis at the time of ZDV initiation (Table 4). There was
a signiﬁcant trend of the odds of anemia with decreasing BMI.
All variables used in the univariable analysis were
included in a multiple regression model, except for
co-trimoxazole prophylaxis. As the program protocol recom-
mended the administration of co-trimoxazole prophylaxis
based on CD4 count, we checked for multicollinearity between
these 2 variables. The correlation coefﬁcient between
co-trimoxazole prophylaxis and CD4 category was found to
be 0.75, and it was, therefore, removed from the analysis.
In the multivariable analysis, the odds of severe anemia
for patients with less than 200 CD4 cells/mm
3 when starting
ZDV-based regimen were 2.40 (95% CI 1.19 to 4.87) greater
thanfor thosewithmorethan200CD4cells/mm
3. Malnutrition,
as deﬁned by BMI less than or equal to 18.0 kg/m
2, was found
to be signiﬁcantly associated with occurrence of severe anemia
(odds ratio = 2.72 CI 1.29 to 5.72) (Table 4).
In an attempt to distinguish anemia induced by ZDV
from that related to concomitant diseases, we looked at the
clinical events reported within 1 month of the lowest Hb level.
Of the 40 patients with grades 3–4 anemia, 4 had an oppor-
tunistic infection: 3 pulmonary tuberculoses and 1 severe
bacterial pneumonia.
ZDV Discontinuation and Mortality
Within 1 year after the switch, ZDV was stopped in 51
patients(9.8%) ofthe study population.The overall rateofZDV
discontinuation was 54/461.61 person-years or 11.70/100
person-years (95% CI 8.96 to 15.27). Forty-three patients
discontinued ZDV because of intolerance: 38 cases of intoler-
ance were due to anemia, 2 had lactic acidosis, 2 developed
myopathy, and 1 developed neutropeniawith anemia. Only mild
and self-limited cases of gastrointestinal intolerance (nausea
and vomiting) were observed. No cases of ZDV-associated
gastrointestinal intolerance requiring treatment discontinuation
were recorded in our program.
One patient with grade 3 anemia died 91 days after ZDV
initiation and 33 days after developing anemia. Mortality rate
was therefore 1/40 for patients who developed at least one
episode of grade 3 or 4 anemia.
Program Challenges
The introduction of the systematic switch resulted in
a number of changes in the clinic including: (1) adjustments in
drug forecasting and procurement to ensure constant supply of
antiretrovirals and reagents for blood tests and blood for
transfusions, (2) simpliﬁcation and rationalization of the ﬂow
of patients to absorb the increased patient load coming for the
extra consultations, (3) organization of additional, speciﬁc
counseling sessions for patients undergoing the regimen
change, (4) elaboration of patient health educational tools on
the d4T- and ZDV-associated adverse events.
For patients previously on HAART for many months and
followed up on a 3-monthly basis, the treatment switch
represented an increase in scheduled appointments, which
disturbed their daily routine. These extra appointments led to
increased absenteeism from work and increased transportation
costs although the latter costs were mostly covered by non-
governmental organizations. The majority of patients understood
the rationale for the treatment change and agreed upon the
additional follow-up visits for clinical and laboratory monitor-
ing. However, 207 patients did not accept the switch mainly
because of the problems associated with the additional follow-up
TABLE 2. Incidence of Anemia Within 1 Year After Initiation
of ZDV-Containing Regimen (n = 520)
Most Severe Episode n (%) Cumulative, n (%)
Grade 4 (,6.5 g/dL) 28 (5.4) 28 (5.4)
Grade 3 (6.5 to ,7.0 g/dL) 9 (1.7) 37 (7.1)
Grade 2 (7.0 to ,8.0 g/dL) 12 (2.3) 49 (9.4)
Grade 1 (8.0 to ,9.5 g/dL) 65 (12.5) 114 (21.9)
Description of the most severe episode experienced by each patient based on all Hb
measurements at scheduled and nonscheduled visits, excluding 7 patients with baseline
Hb , 8.0 g/dL at the time ZDV was started.
TABLE 3. Overall Rates of Incident Anemia After Initiation of
ZDV-Containing Regimen (n = 520)
Anemia
Grade No. Patients No. Person-Years
Rate Per 100
Person-Years
(95% CI)
Grades 1, 2, 3, 4 127 398.95 31.83 (26.75 to 37.88)
Grades 2, 3, 4 56 398.95 14.04 (10.80 to 18.24)
Grades 3, 4 40 398.95 10.03 (7.35 to 13.67)
FIGURE 2. Kaplan–Meier curve showing the grades 1–4
anemia-free probability among the patients systematically
switched to ZDV-based regimen.
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fully understand the rationale of this protocol change.
DISCUSSIONS
To our knowledge, this is the ﬁrst study describing the
results of a systematic switch from d4T to ZDV in a large
cohort of patients after having received an initial HAART
regimen containing d4Tfor a relativelylong time (median time
18 months). The overall survival and the immunological
response in this cohort of patients are comparable to other
studies in resource-poor settings,
2–6 and severe side effects,
besides anemia, were relatively uncommon. However, clinically
signiﬁcant anemia and severe anemia requiring a treatment
change from ZDVoccurred fairly frequently. Although patients
generally understood the rationale for switching and agreed to
the extra visits to monitor side effects, the perceived burden of
extra visits and the consequent work absenteeism were not
acceptable for many others.
Regarding anemia, the median time found for devel-
opment of grades 3–4 anemia was similar to that reported in
a comparable setting in Cambodia.
12 The low prevalence of
diagnosed concomitant infections, at the time of the lowest Hb
level, suggests that most cases of anemia detected were related
to drug toxicity.
Risk factors for human immunodeﬁciency virus (HIV)–
related anemia reported in the literature include advanced
HIV disease, female sex, African origin, low BMI, and older
age.
17–22 Despite the fact that our study population was
relatively young(median age 35), with a median Hb at the time
of the switch of 12.8 g/dL, 75% of them had CD4 counts above
200, 81% presented with normal BMI, and only one third of
them were on co-trimoxazole prophylaxis at the time of the
switch, still an important proportion of them developed
anemia. In a prospective study in West Africa on a cohort of
498 HIV-infected patients, an incidence rate of 9.6/100 person-
years grades 3–4 anemia was reported.
18 Despite the similar
rate observed here, their study population was different with
respect to co-trimoxazole intake
23 (80% had received at base-
line versus 33% in our study population) and prior history of
HAART treatment.
In our cohort, we observed that the risk of developing
severe anemiawas related to malnutrition as measured by BMI
less than 18 kg/m
2 and low CD4 count less than 200/mm
3.
Although the management of severe anemia requiring blood
transfusion can be difﬁcult in ﬁnding a blood donor, the mor-
tality rate was very low in our program setting with 1 death.
Given increasing evidence of d4T-associated long-term
toxicity, clinicians, program managers, and policy makers
want to address this issue, and the switch strategy was
developed as a possible solution. There arevalid arguments for
adopting it. Prescribing a generally well-tolerated d4T-based
regimen for a few months before switching to ZDVallows for
easier stabilization of the patients. This is particularly
important in contexts where many patients have advanced
HIV disease before starting HAART. These patients would be
at higher risk of developing anemia, and it would be difﬁcult
for clinicians to differentiate symptoms of anemia due to ZDV
toxicity from those due to HIV-related illnesses.
Although a recent publication suggested that prior
HAART experience was protective for development of
TABLE 4. Factors Associated With Severe Anemia (grades 3, 4) Within 1 Year After Switching to ZDV-Containing Regimen,
n = 520
Factors Present at Time
of ZDV Switch
Grades 3 and 4 Anemia Univariable Model Multivariable Model
Cases/patients (%) OR 95% CI P OR 95% CI P
Sex
Male 18/224 (8.0) 1.0 — — 1.0 — —
Female 19/296 (6.4) 0.78 0.40 to 1.53 0.48 0.82 0.40 to 1.70 0.596
Age (yrs)
,50 35/494 (7.1) 1.0 — — 1.0 0.18 to 3.88 0.81
$50 2/26 (7.7) 1.09 0.25 to 4.81 0.91 0.83 — —
CD4 cells
$200/mm
3 21/393 (5.3) 1.0 — — 1.0 — —
,200/mm
3 16/127 (12.6) 2.55 1.29 to 5.06 0.007 2.54 1.21 to 5.34 0.013
BMI (kg/m
2)
.18.0 24/424 (5.7) 1.0 — — 1.0 — —
#18.0 13/96 (13.5) 2.61 1.28 to 5.34 0.009 2.84 1.33 to 6.07 0.007
Duration on d4T-based regimen
.18 mos 19/283 (6.7) 1.0 — — 1.0 — —
12–18 mos 12/162 (7.4) 1.11 0.53 to 2.35 0.782 0.82 0.36 to 1.84 0.627
#12 mos 6/75 (8.0) 1.21 0.46 to 3.14 0.698 0.79 0.28 to 2.21 0.660
Co-trimoxazole prophylaxis
No 18/352 (5.1) 1.0 — — — — —
Yes 19/168 (11.3) 2.37 1.21 to 4.64 0.012 —— —
All variableswere included in the multiple regression model except for co-trimoxazole prophylaxis. The P value for the likelihood ratio test for the modelwas 0.0352. All bold values
indicate statistically signiﬁcant factors.
OR, odds ratio.
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12 the incidence of anemia in our study
was comparable to that occurring among populations who were
initiated on ZDV ,
24–26 and the duration on d4T-based regimen
beforeswitch wasnot associatedwith the occurrence ofanemia.
There are several program management concerns
regarding a switch strategy. Patient adherence could poten-
tially be challenged. As a change in treatment regimen might
result in confusion over pill intake, carefully planned
counseling sessions are required and toxicities of drugs have
to be discussed with the patient in detail. In addition, as most
patients are on d4T-based regimens that called for 3-monthly
visits, over many months or years, the intensiﬁed follow-up
required for clinical and laboratory monitoring became
a burden for them. In fact, 207 patients declined the switch,
claiming that the foreseen increased absenteeism of work was
challenging. Despite this, among patients who accepted the
treatment change, we did not experience an increase in missed
or delayed appointments. This was probably the result of the
additional support given to these patients, including ﬁnancial
support for transportation. Both the additional counseling and
increased laboratory monitoring required more clinic appoint-
ments, all adding signiﬁcantly to the workload. This issue has
to be considered as a cost of making the switch.
Huffam et al
12 showed a relatively high proportion
(38%) of patients experiencing a drop in CD4 on at least one
occasion after switching from d4T to ZDV , highlighting
a possible negative impact from a change in HAART regimen.
In our study, 156 (29.8%) patients experienced a drop in CD4
from the time of switch to the end of the observation period.
Even though only few patients were diagnosed with virological
failure, we cannot exclude that the ZDV switch might have led
to a suboptimal CD4 increase and to treatment failures that we
could not detect. The limited access to VL testing in our
program setting did not allow for systematic VL measurement
in patients switched to ZDVand thus did not allow for accurate
evaluation of treatment effectiveness. It is one more example of
the need for readily available, affordable VL technologies in
resource-constrained settings.
Finally, of major concern is the fact that for patients who
developed severe anemia and had to be switched to TDF after
having received d4Tand ZDV, the sequence of future HAART
regimens in the event of treatment failure will be difﬁcult.
On the other hand, TDF is a potent and safer alternative
to both d4T- and ZDV-based standardized ﬁrst-line regimens.
9
Its use as a core drug in ﬁrst-line regimen could avoid the
problems commonly encountered with other NRTIs. Although
laboratory monitoring is required with TDF, associated toxicities
are less frequent than those related to d4T and ZDV.
27,28 This
points to the need to develop low-cost, ﬁxed-dose combinations
containing TDF for the future.
The timing of a switch is still in question. In the previous
study, patients were switched at 6 months whereas our median
switch timing was at 18 months.
12 Choosing the optimum
timing requires balancing the d4T toxicity avoided by the
switch against the increased rate of ZDV-induced anemia and
the extra burdens for patients and the programs.
There are some limitations to the study including the fact
that it was based on program data and did not allow for mea-
surement of the beneﬁts of avoiding d4T toxicity. Information on
concomitant OIs could be incomplete, and a greater proportion of
the anemia observed could then be attributed to opportunistic
infections than ZDV toxicity. The relatively high number of
patients who declined the switch might have inﬂuenced the
results. We compared selected characteristics between this group
and the study population, at different time points (6, 12, and
18 months after HAART initiation) (data not shown). Statistically
signiﬁcant differences found were as follows: a higher CD4 count
at month 18, a higher proportion of women, and a lower propor-
tion of patients on efavirenz-based regimen at 6 and 12 months,
among patients who accepted the switch. It is likely that the
difference in CD4 counts between these 2 groups had no clinical
signiﬁcance as it was observed at only one time point, and all
CD4 count means were above 300 cells/mL. Efavirenz in our
setting was mostly prescribed concomitantly with antituberculosis
treatment. This suggests that there were more patients with
tuberculosis in the group that declined the switch, which could
have led to an underestimation of anemia in the study population,
as tuberculosis is associated with a greater risk of anemia. On the
other hand, the higher proportion of women in our study popu-
l a t i o nm a yh a v el e dt oa no v e r e s t i m a t i o no fa n e m i a ,a sf e m a l es e x
is a known factor for anemia. However, in the univariable and
multivariable analyses, female sex was not found to be associated
with severe anemia in our setting.
The study design did not allow to assess the best time of
switch, and we had to rely upon expert advice. Although
program implications for patient follow-up were reported,
patient satisfaction was not assessed. Randomized controlled
trials could produce stronger evidence on the best switch
strategy in terms of safety and efﬁcacy, especially regarding
long-term treatment success.
Our study showed that after 18 months of d4T-based
HAART, a systematic switch to ZDV in a large cohort of
patients resulted in a relatively high incidence of anemia and
an unexplained drop in CD4 counts in a signiﬁcant number of
patients. Programmatic challenges observed included an
increased laboratory monitoring and adherence counseling,
a heavier workload for staff, and a burden for patients.
Nevertheless, satisfactory overall clinical and immunological
outcomes were recorded in this cohort of patients. Programs in
rural areas in resource-limited settings may neither have the
laboratory capacity for frequent Hb and VL measurements nor
the organizational capacity for an effective implementation of
the switch. If a strategy for substituting ZDV for d4T-based
HAART is to be applied in resource-limited settings, then
ZDV-associated adverse events and context-speciﬁc program-
matic challenges need to be weighed against the expected
beneﬁt of decreased long-term d4T toxicity.
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